Showing results (21-30 of 1,244) with videos related to
Sort By:
Pageof 125
The Lancet. Diabetes & Endocrinology|February 13, 2016
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient dataNaveed Sattar, David Preiss, Jennifer G Robinson, et al.Clinical Science (London, England : 1979)|October 11, 2008
More knocks to the oxidation hypothesis for vascular disease?Adam Mullan, Naveed SattarCurrent Opinion in Lipidology|June 11, 2009
Triglycerides and coronary heart disease: have recent insights yielded conclusive answers?Nadeem Sarwar, Naveed SattarThe Journal of Investigative Dermatology|September 25, 2021
Estimating Cardiovascular Impacts of Drugs for Psoriatic Disease: A Long Way to GoStefan Siebert, Naveed SattarCurrent Cardiology Reports|November 24, 2019
Management of Lipid Abnormalities in Patients with DiabetesAnne Sillars, Naveed SattarCurrent Obesity Reports|August 10, 2021
Obesity as a Risk Factor for Severe COVID-19: Summary of the Best Evidence and Implications for Health CareNaveed Sattar, Jonathan ValabhjiCurrent Diabetes Reports|September 19, 2017
Cardiovascular and Mortality Risks in Migrant South Asians with Type 2 Diabetes: Are We Winning the Battle?Emma Johns, Naveed SattarThe Lancet. Diabetes & Endocrinology|March 14, 2014
Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trialDavid Preiss, Suzanne M Lloyd, Ian Ford, et al.Diabetologia|October 23, 2014
A dysglycaemic effect of statins in diabetes: relevance to clinical practice?Daniel I Swerdlow, Naveed SattarPageof 125